Takeda Partners with Indonesia to Boost Plasma Medicine Access

JAKARTA, Indonesia — Takeda Pharmaceutical Co. Ltd. announced a landmark collaboration with the Indonesian government on July 13, 2026, aimed at revolutionizing the nation's plasma ecosystem. The partnership, which includes the Ministry of Health, the Ministry of Investment and Downstream Industry (BKPM), and the Coordinating Ministry for Economic Affairs, focuses on expanding access to lifesaving plasma-derived medicinal products (PDMPs) while bolstering the country’s domestic healthcare infrastructure.

As part of the multi-phased initiative, Takeda has committed to an initial investment of up to $30 million over the next two years. This funding will support a pilot program to establish a network of plasma donation centers, designed to evaluate operational models before a potential expansion into a nationwide system.

Strengthening Healthcare Resilience

The collaboration is a cornerstone of Indonesia’s broader ambition to become a regional hub for advanced life sciences and biopharmaceutical manufacturing. By integrating international quality standards into the local plasma collection process, the initiative seeks to ensure a reliable, high-quality supply of PDMPs for domestic patients.

"This initiative demonstrates Takeda’s commitment to expanding access to PDMPs, advancing healthcare resilience, and supporting sustainable health systems," said Ramy Riad, President of Plasma-Derived Therapies at Takeda.

The partnership also addresses critical challenges in the ASEAN region, where underdiagnosis and limited access to essential therapies remain significant barriers to care. PDMPs are vital for treating a range of rare and complex chronic diseases, and their inclusion on the World Health Organization’s (WHO) Model List of Essential Medicines underscores their importance to global public health.

Technology Transfer and Economic Impact

Beyond the financial commitment, the collaboration emphasizes workforce development and the transfer of specialized medical expertise. The establishment of plasma centers is expected to create high-skilled employment opportunities, including roles for laboratory technicians and healthcare professionals.

"Beyond the capital commitment, it brings opportunities for technology transfer, talent development, and job creation," noted Rosan P. Roeslani, Minister of Investment and Downstream Industry / Chairman of BKPM. He added that the partnership aligns with Indonesia's strategic goals to attract long-term investments that elevate the national healthcare ecosystem.

Official Sources Section

The collaboration was formalized through a licensing agreement granted by the Ministry of Health of the Republic of Indonesia. Official announcements confirm that Takeda will utilize its global expertise in plasma science—honed through its BioLife plasma services network—to guide the operational standards of the new Indonesian facilities.

Quote Section

"According to officials," the pilot program serves as a critical feasibility phase. Organizers stated that the success of these initial centers will determine the roadmap for scaling the network into a national framework that can sustain long-term demand for plasma-based therapies.

Why It Matters

For Indonesian patients, this partnership represents a major step toward consistent, local access to therapies that are often the only treatment options for rare conditions. For the investment community, it highlights Indonesia’s evolving role in the global biopharmaceutical supply chain, shifting from a dependent importer to an active participant in specialized medical manufacturing.

Key Facts at a Glance

• Investment: Takeda will invest up to $30 million over two years for the pilot program.

• Core Goal: To establish a national plasma donation network and improve domestic access to PDMPs.

• Collaborators: A multi-ministerial effort involving the Indonesian Ministry of Health, BKPM, and the Coordinating Ministry for Economic Affairs.

• Operational Integration: The centers will adopt Takeda’s international quality and regulatory standards, with the first center expected to begin operations in 2027.

Frequently Asked Questions (FAQ)

What are plasma-derived medicinal products (PDMPs)? PDMPs are life-saving therapies made from human plasma that treat rare and chronic diseases, such as immunodeficiencies and hematological disorders.

How will this partnership help Indonesian patients? The initiative aims to build a sustainable domestic supply chain for plasma, reducing reliance on imports and ensuring that patients have reliable access to essential treatments.

What is Takeda’s role in this collaboration? Takeda is providing funding, operational expertise, and technical knowledge to help Indonesia build its own plasma infrastructure, leveraging its global leadership in plasma science.

Source: Takeda Official Newsroom Ministry of Investment and Downstream Industry / BKPM